Overview

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with immunotherapy PD1 inhibitor (pembrolizumab) and standard chemotherapy (nab-paclitaxel) for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with pembrolizumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy in combination with ZEN003694 and standard treatment of chemotherapy may help shrink or stabilize cancer for longer than just chemotherapy alone.

Phase:

Phase 1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Paclitaxel
Pembrolizumab